Muriel F S, Schere D, Barengols A, Eppinger-Helft M, Braier J L, Pavlovsky S, Macchi G H, Guman L
Br J Haematol. 1976 Sep;34(1):119-27. doi: 10.1111/j.1365-2141.1976.tb00180.x.
Thirty-two patients with meningeal leukaemia who achieved meningeal remission with intrathecal methotrexate (MTX) plus dexamethasone (DMT) were entered in a randomized study of two maintenance treatments: (a) I6 patients received intermittent intrathecal doses of MTX plus DMT, and (b) I6 patients received intermittent intrathecal doses of radioactive chromic phosphate (CROP). The population and clinical characteristics of the cases assigned to each maintenance regimen were similar. The duration of meningeal remission was 55-600 + d (median 550 d) for the MTX and DMT group and 56-555 d (median 360 d) for the CROP group. There was no statistical difference (P greater than 0.05) between the curves of the two groups. Intrathecal CROP seems to be as effective as intrathecal MTX plus DMT as maintenance treatment for intrathecal MTX plus DMT induced meningeal remission. Further uses of this compound should be explored but it seems to be dangerous to administer it by lumbar puncture.
32例采用鞘内注射甲氨蝶呤(MTX)加地塞米松(DMT)实现脑膜白血病缓解的患者进入了两种维持治疗的随机研究:(a)16例患者接受鞘内间歇性注射MTX加DMT,(b)16例患者接受鞘内间歇性注射放射性磷酸铬(CROP)。分配到每种维持治疗方案的病例的人群和临床特征相似。MTX和DMT组的脑膜缓解持续时间为55 - 600 +天(中位数550天),CROP组为56 - 555天(中位数360天)。两组曲线之间无统计学差异(P大于0.05)。鞘内注射CROP作为鞘内注射MTX加DMT诱导的脑膜缓解的维持治疗似乎与鞘内注射MTX加DMT一样有效。应探索该化合物的进一步用途,但经腰椎穿刺给药似乎有危险。